Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis by Katchamart, W et al.
Efficacy and toxicity of methotrexate (MTX)
monotherapy versus MTX combination therapy with
non-biological disease-modifying antirheumatic drugs
in rheumatoid arthritis: a systematic review and
meta-analysis
W Katchamart,
1,2 J Trudeau,
3 V Phumethum,
1 C Bombardier
4,5
c Additional figures and
appendixes are published online
only at http://ard.bmj.com/
content/vol68/issue7
1Rheumatology Division,
Department of Medicine,
University of Toronto, Toronto,
Ontario, Canada;
2Rheumatology Division,
Department of Medicine, Siriraj
Hospital, Mahidol University,
Bangkok, Thailand;
3Ho ˆspital
Notre-Dame, Department of
Rheumatology, Montreal,
Canada;
4Division of
Rheumatology and Department
of Health Policy, Management,
and Evaluation, University of
Toronto, Toronto, Ontario,
Canada;
5Division of Clinical
Decision Making and Health
Care, Toronto General Research
Institute, University Health
Network, Toronto, Ontario,
Canada
Correspondence to:
Dr C Bombardier, Institute for
Work and Health, 481 University
Avenue, Suite 800, Toronto,
Ontario M5G 2E9, Canada;
claire.bombardier@utoronto.ca
Accepted 17 November 2008
Published Online First
3 December 2008
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
ard.bmj.com/info/unlocked.dtl
ABSTRACT
Objective: To evaluate the efficacy and toxicity of
methotrexate (MTX) monotherapy compared with MTX
combination with non-biological disease-modifying anti-
rheumatic drugs (DMARDs) in adults with rheumatoid
arthritis.
Method: A systematic review of randomised trials
comparing MTX alone and in combination with other non-
biological DMARDs was carried out. Trials were identified
in Medline, EMBASE, the Cochrane Library and ACR/
EULAR meeting abstracts. Primary outcomes were
withdrawals for adverse events or lack of efficacy.
Results: A total of 19 trials (2025 patients) from 6938
citations were grouped by the type of patients
randomised. Trials in DMARD naive patients showed no
significant advantage of the MTX combination versus
monotherapy; withdrawals for lack of efficacy or toxicity
were similar in both groups (relative risk (RR)=1.16;
95% CI 0.70 to 1.93). Trials in MTX or non-MTX DMARD
inadequate responder patients also showed no difference
in withdrawal rates between the MTX combo versus
mono groups (RR=0.86; 95% CI 0.49 to 1.51 and
RR=0.75; 95% CI 0.41 to 1.35), but in one study the
specific combination of MTX with sulfasalazine and
hydroxychloroquine showed a better efficacy/toxicity ratio
than MTX alone with RR=0.3 (95% CI 0.14 to 0.65).
Adding leflunomide to MTX non-responders improved
efficacy but increased the risk of gastrointestinal side
effects and liver toxicity. Withdrawals for toxicity were
most significant with ciclosporin and azathioprine
combinations.
Conclusion: In DMARD naive patients the balance of
efficacy/toxicity favours MTX monotherapy. In DMARD
inadequate responders the evidence is inconclusive. Trials
are needed that compare currently used MTX doses and
combination therapies.
Methotrexate (MTX) is among the most effective
disease-modifying antirheumatic drugs (DMARDs)
in rheumatoid arthritis (RA) with less toxicity and
better tolerability. Unfortunately, MTX alone may
not fully control disease activity. Increasingly,
MTX is used in combination with other non-
biological DMARDs.
1–3
Many MTX and traditional DMARDs combina-
tion regimens have been studied, but several
important questions remain.
4–6 What is the relative
benefit and toxicity of MTX mono versus MTX
combination with DMARDs? When should the
combination DMARD therapy be used: initially or
only after a trial of MTX monotherapy? Finally,
which is the preferred combination DMARD
strategy? These questions are particularly salient
as formularies in many countries require the use of
MTX mono and MTX combo therapies before
reimbursing for the more expensive biological
drugs. The objective of this paper was to system-
atically review randomised trials that compared
MTX monotherapy with MTX in combination
with other non-biological DMARDs. This manu-
script is part of the 3E (Evidence, Expertise and
Exchange) Initiative described in more details in
the same issue of this journal.
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MATERIALS AND METHODS
Literature search
We performed a search of electronic bibliographic
databases including Medline (1950 to June week 3
2007), EMBASE (1980 to 2007 week 25) and the
Cochrane Central Register of Controlled Trials
(2nd quarter 2007) using a search strategy that
combined terms for ‘‘rheumatoid arthritis’’,
‘‘methotrexate’’ and ‘‘randomised controlled trials’’
(full search strategy available online at http://
www.annrheumdis.com/supplemental). We also
searched the abstracts of the Annual scientific
meetings of the American College of
Rheumatology (ACR) and European League
Against Rheumatism (EULAR) from 2005 to
2007, the references lists of all relevant studies,
letters and review articles, and all languages were
included.
Study selection
Two reviewers (WK, JT) independently screened
the titles and abstracts of the citations and
retrieved relevant articles. The following selection
criteria were used: (a)r a n d o m i s e dc o n t r o l l e d
trials of MTX monotherapy versus MTX com-
bined with other DMARDs of at least 12 weeks of
trial duration (open-label extensions were
excluded as well as studies comparing DMARDs
not currently used—for example, oral gold); (b)
patients with RA >18 years old; (c)d a t aa v a i l a b l e
on one or more of following prespecified out-
comes: ACR core set
8;A C R2 0 ,5 0o r7 0
responses
9; ACR remission
10;D i s e a s eA c t i v i t y
Score (DAS)
11 12; EULAR response
13;w i t h d r a w a l
d u et ol a c ko fe f f i c a c yo ra d v e r s ee v e n t s( A E s ) ;
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Data abstraction and quality assessment
Two reviewers (WK, VP) independently extracted the data and
assessed the quality of relevant studies. Study quality was
assessed using van Tulder ‘s scale.
14 This scale comprises 11
questions, including randomisation, blinding procedure
(patients, provider and outcome assessor), concealed treatment
allocation, similarity of the important baseline characteristics,
co-intervention, timing of the outcome assessment, compliance
and withdrawals and intention-to-treat analysis. Each item is
rated as ‘‘yes’’=1 and ‘‘no or do not know’’ =0. The score
ranges from 0 to 11.
Data synthesis
We used RevMan 4.2.10 for analysis. The efficacy analysis was
stratified into three groups based on previous DMARD use. The
‘‘DMARD naı ¨ve, parallel strategy’’ refers to trials in which
patients who never received DMARDs (including MTX) were
randomised to start MTX alone or MTX plus another DMARD;
The ‘‘MTX inadequate response, step-up strategy’’ refers to
trials in which patients with inadequate response to MTX were
randomised to continue the use of MTX alone or to add a
second DMARD. The ‘‘non-MTX DMARDs inadequate
response, step-up strategy’’ refers to trials where patients with
inadequate response to DMARDs (other than MTX) were
randomly switched to MTX alone or MTX plus another
DMARD. The toxicity analysis was stratified by DMARD
combination and pooled across trials for each combination.
For continuous measures of efficacy, we used either end of
trial data or change from baseline and pooled them as weighted
mean differences using a random effect model.
15 For the
categorical measures of efficacy, the end of trial results were
pooled and estimated using the relative risk (RR) with random
effect model. An RR .1 favours MTX combination therapy. For
the analysis of patient withdrawals, an RR .1 favours MTX
monotherapy (MTX monotherapy results in less withdrawal
than MTX combination). Our prespecified primary analysis was
based on total withdrawal rates for efficacy or toxicity.
Figure 1 Results of the literature search
and disposition of the potentially relevant
studies. *Number is not equal to the sum
of the number from each database owing
to duplication among databases. ACR,
American College of rheumatology; CCRT,
Cochrane Central Register of Controlled
Trials; DMARD, disease-modifying
antirheumatic drug; EULAR, European
League Against Rheumatism; MTX,
methotrexate; RA, rheumatoid arthritis;
RCT, randomised controlled trial.
Table 1 Excluded studies and reason for exclusion
Study Reason for exclusion
Calguneri, 1999 No methotrexate monotherapy arm (data combined with
sulfazalazine and hydroxychloroquine monotherapy)
Clegg, 1997 No outcome of interest
Haagsma, 1995 Summary of Haagsma et al. (included in this review)
27
Kremer, 2004 Open-label extension of randomised controlled trial
Maillefert, 2003 Open-label extension of randomised controlled trial
Matucci-Cerinic, 2003 Summary of Kremer et al. (included in this review)
20
Mottaghi, 2005 Non-randomised controlled trial
Mroczkowski, 1999 Open-label extension of randomised controlled trial
Nagashima, 2006 Non-randomised controlled trial
Nisar, 1994 Non-randomised controlled trial
O’Dell, 1996 Open-label extension of randomised controlled trial
Rau, 1998 Non-randomised controlled trial
Stein, 1997 Open-label extension of randomised controlled trial
Trnavsky, 1993 No methotrexate monotherapy arm
Willkens, 1996 Published in the journal supplements and the key data have
been reported in Willkens et al (included in this review)
25
Krause D et al (German),
1998
Non-randomised controlled trial
Geokoop-Ruiterman
YPM, 2005
No MTX monotherapy arm
Geokoop-Ruiterman
YPM, 2007
No MTX monotherapy arm
Mottonen T et al, 1999 No MTX monotherapy arm
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RESULTS
Our search retrieved 6938 citations. After review of titles and
abstracts and removal of duplicates across databases, 39 full-text
articles were retrieved for further evaluation and 20 articles
(from 19 studies) were retained for our analysis (fig 1). Table 1
summarises the excluded studies and reason for exclusion.
Characteristics of the included studies
Table 2 gives the characteristics of the included studies. The
total number of patients in the trials was 2025. Most of the
trials were 6 or 12 months in duration. The doses of MTX
ranged between 5 and 18 mg/week but most were between 7
and 15 mg/week. MTX was administered orally in all trials.
Methodological quality of studies
Ten studies
16–18 20 21 24–26 28 31 demonstrated appropriate randomi-
sation, adequate blinding of intervention in both patients and
care providers as well as clearly reported number and reason for
withdrawal and drop out. Seven of these
16 17 20 24–26 28 were high-
quality (comparison groups had similar baseline characteristics
and co-interventions and acceptable withdrawals and drop
outs) but one study
18 had a high drop-out rate (,59%). In two
studies,
21 31 there were unequal co-interventions including
steroid or non-steroidal anti-inflammatory drugs (NSAIDs)
between the treatment groups. One of these
21 also had a high
drop-out rate in the MTX +placebo group due to lack of efficacy
(52% vs 24% in MTX vs MTX+gold, respectively).
In five studies,
61 92 22 33 0the method of randomisation was not
explicitly described; additionally co-intervention was either
unclear
61 9 or higher
22 30 (NSAIDS or steroid) in the MTX
treatment group
Owing to their open-label nature, five studies
452 72 93 2were
rated lower and in three the method of randomisation was also
unclear.
52 93 2
Efficacy
DMARD naı ¨ve, parallel design
The ACR responses were available in three of the six trials that
compared MTX mono with MTX combo therapies in MTX
naı ¨ve patients (fig 2).These trials included a total of 287
patients. Combinations arms were MTX+ciclosporin (CSA)
41 7
and MTX+doxycycline,
18 The only significant result was for the
ACR 70 response in one CSA trial with RR=2.41 (95% CI 1.07
to 5.44) favouring the MTX combination arm.
The EULAR response was available in an additional two trials
(368 patients) with combination of MTX+ sulfasalazine
(SSZ)
61 6 or MTX+CSA
17 (fig A, online only). There was no
significant difference between the two groups for a ‘‘good’’ or
‘‘moderate’’ EULAR response or remission.
The number of patients who withdrew owing to lack of
efficacy was available in five of the six trials (405 patients)
with combination of MTX+SSZ,
561 6 MTX+CSA
4 and
MTX+doxycycline
18 (fig B, online only). MTX combination
therapy resulted in less patient withdrawal than monotherapy
but it was not significant (RR=0.63, 95% CI 0.34 to 1.17)
furthermore, the number of patients who withdrew because of
Table 2 Characteristic of included studies
Study
Sample
size
Study
duration
(months) Strategy*
MTX (mg/week)
DMARD
Quality
rating{
(0–11) Mono Combo
Haagsma, 1997
16 105 12 DMARD-N 15 7.5 SSZ 3 g/day 10
Dougados, 1999
6 209 12 DMARD-N Up to 15 Up to 15 SSZ 3 g/day 7
Marchesoni,
2003
4
61 12 DMARD-N 11.2 9.5 CSA 2.5 mg/kg/day 8
Tascioglu, 2003
5 70 12 DMARD-N 7.5 7.5 SSZ 2 g/day 5
Hetland, 2006
17 160 12 DMARD-N 15 12.5 CSA 2.5 mg/kg/day 9
O’Dell, 2006
18 66 24 DMARD-N 7.5–17.5 7.5–17.5 DOXY 20 or 100 mg
twice/day
7
Tugwell, 1995
19 148 6 MTX-IR 15 15 CSA 2.5–5 mg/kg/day 7
Kremer, 2002
20 263 6 MTX-IR 16.1 16.8 LEF 20 mg/day 10
Lehman, 2005
21 65 12 MTX-IR 18 18 IM gold 50 mg/week 8
Jarrett, 2005
22 39 6 MTX-IR 11.9 14 Zolendronic acid 5 mg
IV twice
7
Ogrendik, 2007
23 76 6 MTX-IR 17.5 15 LEV 500 mg/day 8
Willkens, 1992,
24
1995
25
212 6 Non-MTX-IR 5–15 5–15 AZA 50–150 mg/day 8
Ferraz, 1994
26 82 6 Non-MTX-IR 7.5 7.5 CQ 250 mg/day 9
Haagsma, 1994
27 40 6 Non-MTX-IR 8.3 7.9 SSZ 2 g/day 7
O’Dell, 1996
28 102 6 Non-MTX-IR Up to
17.5
Up to 17.5 SSZ 1 g/day
HCQ 400 mg/day
9
Hanyu, 1999
29 37 60 Non-MTX-IR 7.5 5 Previous DMARD
(penicillamine, BUC, IM
gold)
3
Ichikawa, 2005
30 71 24 Non-MTX-IR 8 8 BUC 200 mg/day 7
Capell, 2007
31 165 12 Non-MTX-IR 15 12.5 SSZ 2 g/day 8
Islam, 2000
32 54 6 Not clear 7.5–15 SSZ 2 g/day 3
Our analysis included data only from patients in the MTX¡placebo and MTX+other DMARDS arms (n=158).
*DMARD-N, disease-modifying antirheumatic drug naı ¨ve patients; MTX-IR, methotrexate inadequate response patients; non-MTX-
IR, non-MTX DMARDs inadequate response patients; {Van Tulder’s scale.
AZA, azathioprine; BUC, bucillamine; CQ, chloroquine; CSA, ciclosporin; DOXY, doxycycline; HCQ, hydroxychloroquine; IM gold,
intramuscular gold; LEF, leflunomide; LEV, levofloxacin; SSZ, sulfasalazine.
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(fig C, online only).
MTX inadequate response, step-up design
The ACR responses were available in four of five trials (552
patients) that compared MTX mono with MTX combo
therapies in MTX inadequate response patients (fig 3).
Combination arms included MTX+leflunomide (LEF),
20
MTX+CSA,
19 MTX+ intramuscular gold (IM gold)
21 and
MTX+ levofloxacin.
23 In this group of trials combination
therapy was significantly more effective than MTX mono-
therapy with RR=2.51 (95% CI 1.92 to 3.28), RR=4.54 (95%
CI 2.51 to 8.20) and RR=5.59 (95% CI 2.08 to 15.01) for ACR
20, 50 and 70 response, respectively. There were no data on
ACR remission and EULAR response.
The number of patients who withdrew owing to lack of
efficacy was available in three of the five trials (476 patients)
with combination of MTX+LEF,
20 MTX+CSA
19 and MTX+ IM
gold
21 (fig B, online only), showing significantly fewer patient
withdrawals than in the MTX monotherapy group with
RR=0.42 (95% CI 0.21 to 0.84). However, the number of
patients who withdrew because of toxicity was significantly
increased 1.89 (95% CI 1.05 to 3.41) (fig C, online only).
Non-MTX DMARD inadequate response, step-up design
The ACR responses were available in two of eight trials (158
patients) that compared MTX mono with MTX combo
therapies in non-MTX inadequate responders (fig 4). Only the
pooled ACR 20 showed a significant benefits for the combina-
tion of MTX+SSZ
31 and MTX+bucillamine (BUC)
30 over
monotherapy with RR=1.85 (95% CI 1.21 to 2.83). There
were no data on ACR remission.
The EULAR response criteria were available for one of these
two studies
31 (fig D, online only) and showed no statistically
significant different between two groups.
Figure 2 American College of
Rheumatology (ACR) response: MTX
combination vs MTX monotherapy in
DMARD naı ¨ve group. CSA, ciclosporin;
DMARD, disease-modifying antirheumatic
drug; DOXY, doxycycline; MTX,
methotrexate.
Figure 3 American College of
Rheumatology (ACR) response: MTX
combination vs MTX monotherapy in
MTX inadequate response group. CSA,
ciclosporin; IM gold, intramuscular gold;
LEF, leflunomide; LEV, levofloxacin; MTX,
methotrexate.
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efficacy was available in five of eight trials (329 patients) with
combination of MTX+chloroquine (CQ),
26 MTX+SSZ+
hydroxychloroquine (HCQ),
33 MTX+SSZ,
31 MTX+BUC
30 and
MTX+ previous DMARDs (BUC, D-penicillamine and IM
gold).
29 MTX combination therapy yielded significantly fewer
patient withdrawals than monotherapy with RR=0.37 and
95% CI 0.16 to 0.87 (fig B, online only).
Toxicity
Number of total or individual reported adverse events
The azathioprine
25 and IM gold
21 MTX combinations increased
the risk of the number of total side effects RR=1.67 (95% CI
1.21 to 2.3) and RR=2.61 (95% CI 1.22 to 5.55), respectively.
The sulfasalazine
561 62 7and leflunomide
20 MTX combinations
increased the risk of gastrointestinal (GI) side effects (RR=1.75,
95% CI 1.14 to 2.67 and RR=1.67, 95% CI 1.17 to 2.4,
respectively). The leflunomide MTX combination
20 also
increased the risk of an abnormal liver function test with
RR=4.3 (95% CI 2.58 to 7.15).
Withdrawal due to adverse reaction
In 17 of the 19 trials (1624 patients: 824 in combination group
vs 800 monotherapy group) combination therapy resulted in
more withdrawal due to adverse reactions than monotherapy
but the differences were significant only for the CSA
41 71 9and
azathioprine
24 combinations with RR=1.88, 95% CI 1.02 to
3.50) and RR=5.18 (95% CI 1.58 to16.96), respectively (fig 5).
Combined withdrawal due to lack of efficacy and toxicity (fig 6)
Our primary analysis was based on withdrawals for both
efficacy and safety; data were available for 13 of the 19 trials. In
DMARD naı ¨ve patients as well as in MTX inadequate
responders pooled results showed no advantage of combination
therapy over MTX monotherapy (RR=1.16, 95% CI 0.70 to
1.93 and RR=0.86, 95% CI 0.49 to 1.51, respectively). The non-
MTX DMARD inadequate responders also showed no advan-
tage of combination therapy (RR=0.75, 95% CI 0.41 to 1.35).
However, there was significant heterogeneity in this group
(I
2=57.4%) with one important outlier: the combination of
MTX+SSZ+HCQ showed a better efficacy/toxicity ratio than
MTX alone with RR=0.3 (95% CI 0.14 to 0.65).
DISCUSSION
Despite the introduction of new biological treatments, MTX
alone or in combination with other traditional DMARDs
remain the recommended first-line treatments for most patients
with RA. Our systematic review examined their respective risks
and benefits. The simplest criterion of benefit/risk ratio for drug
evaluation is whether a drug is stopped owing to inefficacy or
AEs. These data were available for 13/19 trials and therefore
represent the most powerful results from our meta-analysis.
Overall, there were no benefits of MTX combo over mono-
therapy either within the three design strategies or across all
trials (RR=0.89, 95% CI 0.66 to 1.21) (fig 6). However, one
study of the combination MTX, SSZ and HCQ showed better
efficacy/toxicity ratio than MTX alone with RR=0.3 (95% CI
0.14 to 0.65).
Outcome measures other than withdrawals were not
reported consistently across trials. In the ‘‘DMARD naı ¨ve,
parallel strategy’’ ACR responses showed a significant improve-
ment for the combination therapies only for the ACR 70 but
with increasing risk of withdrawals due to toxicity.
Additionally, none of the trials that reported other composite
or single outcome measures could demonstrate a benefit of an
initial course of combination therapy over MTX monotherapy
in DMARD naı ¨ve patients.
In the ‘‘MTX inadequate response, step-up strategy’’ four
trials that reported ACR responses showed that combination
therapy was significantly more effective than MTX mono-
therapy (with an equally significant increase in risk of
withdrawal for toxicity). These trials, however, do not reflect
current practice. The dose of MTX (7–15 mg/week) is lower
than current use and patients randomised to the MTX
monotherapy arm continued to receive the same inadequate
low dose of MTX. In actual practice doctors would increase the
dose of MTX or change to parenteral administration before
adding another DMARD. Therefore, the current evidence in
patients with inadequate response to MTX is inconclusive
pending results from new trials that compare maximum doses
of MTX monotherapy with combination therapies.
In the ‘‘non-MTX DMARDs inadequate response, step-up
strategy’’ only two studies
30 31 were available for the ACR
response analysis. Unfortunately, no conclusions can be
reached. In Capell’s study, patients for whom SSZ 2 g/day
had already failed were randomised to receive MTX alone or
MTX + the ‘‘same dose’’ of SSZ; so in reality this was a study
comparing MTX in both arms. The second is a trial of
bucillamine which is not commonly used in North America or
Europe.
For toxicity analyses, GI and liver adverse events were higher
in the sulfasalazine and leflunomide MTX combinations but did
Figure 4 American College of
Rheumatology (ACR) response: MTX
combination vs MTX monotherapy in non-
MTX inadequate response group. BUC,
bucillamine; MTX, methotrexate; SSZ,
sulfasalazine.
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reaction stratified by combination of
disease-modifying antirheumatic drugs
(DMARDs). AZA, azathioprine; BUC,
bucillamine; CSA, ciclosporin; CQ,
chloroquine; HCQ, hydroxychloroquine;
IM gold, intramuscular gold; LEF,
leflunomide; MTX, methotrexate; SSZ,
sulfasalazine.
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1110 Ann Rheum Dis 2009;68:1105–1112. doi:10.1136/ard.2008.099861not lead to significant differences in withdrawal rates. The total
number of side effects was higher with gold and azathioprine
MTX combinations. Withdrawal rates due to adverse reactions
were higher in all the combination therapies, but the differences
were significant only for the combinations of MTX+ciclosporin
and MTX+azathioprine.
There are important limitations to our analyses; many of the
studies included a small number of patients; most used lower
doses of MTX than in current practice and had different length
of follow-up and several studies were done with drugs that are
not commonly used (bucillamine, doxycycline, levofloxacin,
chloroquine, IM gold and ciclosporin). Furthermore, most of the
combinations were studied in only one or two trials, except the
combination MTX+SSZ, which included five trials. Also,
outcome measures were inconsistently reported; European trials
used DAS or DAS28 while others reported ACR responses, some
(studies before 2000) reported only individual clinical and
laboratory outcomes. All these limitations complicate the
pooling of results across studies. Nonetheless, this meta-analysis
presents useful information, particularly when looking at total
withdrawal rates where combination across a number of studies
is possible.
Three previous systematic reviews
34–36 and two meta-ana-
lyses
37 38 compared DMARD monotherapy with combination
therapy. Felson et al (1994)
37 and Verhoeven et al (1998)
35
concluded that combination DMARD therapy does not
substantially improve efficacy and toxicity is increased; this is
consistent with our overall results that included more recent
trials. Hochberg et al (2001)
36 included only MTX inadequate
responder studies and found that ACR responses improved
significantly when a second DMARD was added. Choy et al
(2005)
38 reached the same conclusion in this subgroup of
patients based on analysis of withdrawals but added that
improved efficacy is associated with an increased risk of adverse
events. Donahue et al (2008)
34 reported only on a small subset of
our included trials (mostly of sulfasalazine combinations) and
the remainder of his and Choy’s data cannot be compared with
our study because they included biologic agents as well as
monotherapies with non-biological DMARDs other than MTX.
In summary, when the balance of efficacy and toxicity is
taken into account, the evidence from our systematic review
showed no significant advantage of the MTX combination
versus monotherapy; only one study with the specific combina-
tion of MTX+SSZ+HCQ showed a better efficacy/toxicity ratio
than MTX alone. Adding leflunomide to MTX non-responders
improved efficacy but increased the risk of GI side effects and
liver toxicity. Withdrawals because of toxicity varied but were
most significant with ciclosporin and azathioprine combina-
tions. Trials are needed that compare currently used MTX doses
and combination therapies.
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APPENDIX
The results and figures of the search strategy (appendix 1), efficacy (EULAR response,
withdrawal due to lack of efficacy, significant results of continuous data) and toxicity
(appendix 2) are available on the website.
Extended report
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